T-Cell Immunotherapy Market - Forecasts from 2018 to 2023

T-Cell Immunotherapy Market - Forecasts from 2018 to 2023

The T-Cell Immunotherapy market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2023, from US$XX.XXX billion in 2017. T-Cell immunotherapy changes body immune cells and help them to kill cancer cells. Rising prevalence of cancer and lack of ideal biomarkers for early detection of cancer is considered as the driving factor for the growth of the market. According to World Health Organization cancer is responsible for an estimated 9.6 million deaths in 2018 and nearly 70% of the deaths from cancer occur in low and middle income countries. However, side effects and health issues associated with CAR T-Cell therapy is considered as the restraining factor for the growth of the market.  

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the T-Cell Immunotherapy value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the T-Cell Immunotherapy market.

Major industry players profiled as part of the report are Cellular Biomedicine Group, Autolus Novartis, Kite Pharma, Adaptimmune Therapeutics and Cellectis among others.

Segmentation

The T-Cell Immunotherapy market has been analyzed through following segments:

By Type

Chimeric antigen receptor (CAR)

T-cell receptor (TCR)

Tumor infiltrating lymphocyte (TIL)


By Indication

Melanoma

Leukemia

Ovarian cancer

Others


By Geography

North America

USA

Canada

Mexico

Others


South America

Brazil

Argentina

Others


Europe

Germany

France

United Kingdom

Spain

Others


Middle East and Africa


Asia Pacific

China

Japan

India

Others


Target audience

Manufacturers

Suppliers

Distributors

Service Providers

Government Agencies

Research Organizations

Consultants


Key insights offered

What will be the T-Cell Immunotherapy market size from 2017 to 2023?

How are the major drivers and restraints affecting the T-Cell Immunotherapy market growth and the opportunities which exist for key vendors?

Which segment and region will drive or lead the market growth and why?

A comprehensive analysis of competitive landscape and key market participants’ behaviour

Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth.

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY  
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. T-CELL IMMUNOTHERAPY  MARKET BY TYPE
5.1. Chimeric antigen receptor (CAR) T-cell
5.2. T-cell receptor (TCR)
5.3. Tumor infiltrating lymphocyte (TIL)
6. T-CELL IMMUNOTHERAPY  MARKET BY INDICATION 
6.1. Melanoma 
6.2. Leukemia 
6.3. Ovarian cancer
6.4. Others
7. T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentia
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Others
7.4. Middle East and Africa
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. Others
8. COMPETITIVE INTELLIGENCE
8.1.  Market Share of Key Players
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Cellular Biomedicine Group
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. Autolus Novartis
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Kite Pharma
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Adaptimmune Therapeutics 
9.4.1. Financials
9.4.2. Products and Services
9.4.3. Recent Developments
9.5. Cellectis
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. Bluebird bio 
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Immunocore
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Innovative Cellular Therapeutics
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. Iovance Biotherapeutics
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. Celgene
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES
DISCLAIMER 

Cellular Biomedicine Group

Autolus Novartis

Kite Pharma

Adaptimmune Therapeutics

Cellectis

Bluebird bio

Immunocore

Innovative Cellular Therapeutics

Iovance Biotherapeutics

Celgene

  • SKU:
  • Publishing Date: 2018-11-02
  • Product Code: 1
  • Availability: In Stock
  • $3,800.00
  • Ex Tax: $3,800.00

Available Options